论文部分内容阅读
目的比较米力农和左西孟旦治疗失代偿心力衰竭的临床疗效。方法选取2012年6月—2015年12月于乾安镇中心卫生院接受治疗的失代偿心力衰竭患者120例,根据随机对照、平行、单盲的原则将其分为对照组(60例)和观察组(60例)。对照组给予米力农治疗,观察组给予左西孟旦治疗。比较两组患者的症状消失时间、动脉血氧分压、动脉血二氧化碳分压以及不良反应发生情况。结果观察组心率减慢时间、水肿消退时间、咳嗽改善时间短于对照组,动脉血氧分压高于对照组,动脉血二氧化碳分压低于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论左西孟旦治疗失代偿心力衰竭患者的疗效较米力农更佳,而且安全可靠。
Objective To compare the clinical efficacy of milrinone and levosimendan in the treatment of decompensated heart failure. Methods A total of 120 patients with decompensated heart failure who received treatment at the Central Hospital of Qian’an from June 2012 to December 2015 were selected and randomly divided into control group (60 cases), control group And observation group (60 cases). The control group was given Milrinone treatment, the observation group was given levosimendan treatment. The symptom disappearance time, arterial partial pressure of oxygen, partial pressure of arterial carbon dioxide and the incidence of adverse reactions were compared between the two groups. Results The observation group had slower heartbeat time, edema subsidence time, cough improvement time shorter than the control group, arterial oxygen partial pressure higher than the control group, arterial carbon dioxide partial pressure lower than the control group, the adverse reaction rate was lower than the control group, the difference was Statistical significance (P <0.05). Conclusion Levosimendan treatment of decompensated heart failure patients with miller benefit better, and safe and reliable.